Hypoparathyroidism, familial isolated, 2

disease
On this page

Also known as FIH2hypoparathyroidism, familial isolated 2

Summary

Hypoparathyroidism, familial isolated, 2 (MONDO:0020798) is a disease caused by GCM2 (GenCC Strong), with 1 cohort gene.

At a glance

  • Causal gene: GCM2 (GenCC Strong)
  • Cohort genes: 1
  • ClinVar variants: 92

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namehypoparathyroidism, familial isolated, 2
Mondo IDMONDO:0020798
OMIM618883
DOIDDOID:0061151
UMLSC5394383
MedGen1715177
GARD0018257
Is cancer (heuristic)no

Also known as: FIH2 · hypoparathyroidism, familial isolated 2 · hypoparathyroidism, familial isolated, 2

Data availability: 92 ClinVar variants · 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by body system or component › endocrine system disorderparathyroid gland disorderhypoparathyroidismhereditary hypoparathyroidismfamilial hypoparathyroidismhypoparathyroidism, familial isolated, 2

Related subtypes (2): hypoparathyroidism, familial isolated 1, autosomal dominant hypocalcemia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

92 retrieved; paginated sample, class counts are floors:

66 uncertain significance, 8 likely pathogenic, 6 conflicting classifications of pathogenicity, 5 pathogenic, 4 benign/likely benign, 3 likely benign

ClinVarVariant (HGVS)GeneClassificationReview
1065410NM_004752.4(GCM2):c.1400del (p.Pro467fs)GCM2Pathogenicno assertion criteria provided
1065411NM_004752.4(GCM2):c.1389del (p.His465fs)GCM2Pathogenicno assertion criteria provided
6090NG_008970.1:g.3172_(10967_10971)delGCM2Pathogenicno assertion criteria provided
6091NM_004752.4(GCM2):c.140G>T (p.Arg47Leu)GCM2Pathogeniccriteria provided, single submitter
64623NM_004752.4(GCM2):c.893del (p.Ile298fs)GCM2Pathogenicno assertion criteria provided
1341348NM_004752.4(GCM2):c.1148T>C (p.Ile383Thr)GCM2Likely pathogeniccriteria provided, single submitter
2444139NM_004752.4(GCM2):c.853del (p.Ser285fs)GCM2Likely pathogeniccriteria provided, single submitter
3041710NM_004752.4(GCM2):c.199C>T (p.Arg67Cys)GCM2Likely pathogeniccriteria provided, multiple submitters, no conflicts
3068139NM_004752.4(GCM2):c.199C>G (p.Arg67Gly)GCM2Likely pathogeniccriteria provided, single submitter
3391440NM_004752.4(GCM2):c.1098C>A (p.Cys366Ter)GCM2Likely pathogeniccriteria provided, single submitter
3592949NM_004752.4(GCM2):c.1216C>T (p.Arg406Ter)GCM2Likely pathogeniccriteria provided, single submitter
3592955NM_004752.4(GCM2):c.1100_1103del (p.Arg367fs)GCM2Likely pathogeniccriteria provided, single submitter
3592958NM_004752.4(GCM2):c.1048C>T (p.Gln350Ter)GCM2Likely pathogeniccriteria provided, single submitter
1324460NM_004752.4(GCM2):c.1109C>T (p.Thr370Met)GCM2Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1707105NM_004752.4(GCM2):c.139C>T (p.Arg47Cys)GCM2Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
2394494NM_004752.4(GCM2):c.22G>A (p.Glu8Lys)GCM2Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
355008NM_004752.4(GCM2):c.1181A>C (p.Tyr394Ser)GCM2Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
6092NM_004752.4(GCM2):c.187G>A (p.Gly63Ser)GCM2Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
904503NM_004752.4(GCM2):c.1342A>G (p.Met448Val)GCM2Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1705397NM_004752.4(GCM2):c.301C>G (p.Leu101Val)GCM2Uncertain significancecriteria provided, single submitter
1711852NM_004752.4(GCM2):c.60C>A (p.Ser20Arg)GCM2Uncertain significancecriteria provided, multiple submitters, no conflicts
1992385NM_004752.4(GCM2):c.523A>T (p.Ile175Phe)GCM2Uncertain significancecriteria provided, multiple submitters, no conflicts
1999959NM_004752.4(GCM2):c.1352C>T (p.Ala451Val)GCM2Uncertain significancecriteria provided, multiple submitters, no conflicts
2285256NM_004752.4(GCM2):c.1343T>A (p.Met448Lys)GCM2Uncertain significancecriteria provided, multiple submitters, no conflicts
2286665NM_004752.4(GCM2):c.1484T>C (p.Val495Ala)GCM2Uncertain significancecriteria provided, multiple submitters, no conflicts
2324309NM_004752.4(GCM2):c.443C>T (p.Ala148Val)GCM2Uncertain significancecriteria provided, multiple submitters, no conflicts
2734824NM_004752.4(GCM2):c.175C>T (p.Arg59Cys)GCM2Uncertain significancecriteria provided, multiple submitters, no conflicts
3099047NM_004752.4(GCM2):c.547T>C (p.Tyr183His)GCM2Uncertain significancecriteria provided, multiple submitters, no conflicts
3235973NM_004752.4(GCM2):c.513AAG[1] (p.Arg172del)GCM2Uncertain significancecriteria provided, single submitter
355007NM_004752.4(GCM2):c.1364G>A (p.Arg455Gln)GCM2Uncertain significancecriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 5 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
GCM2StrongAutosomal recessivehypoparathyroidism, familial isolated, 25

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
GCM2Orphanet:2239Familial isolated hypoparathyroidism due to agenesis of parathyroid gland
GCM2Orphanet:99879Familial isolated hyperparathyroidism

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
GCM2HGNC:4198ENSG00000124827O75603Chorion-specific transcription factor GCMbgencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
GCM2Chorion-specific transcription factor GCMbTranscription factor that binds specific sequences on gene promoters and activate their transcription.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
GCM2Other/UnknownnoTscrpt_reg_GCM, GCM_dom_sf, GCM

Expression context

Cohort genes with no expression data: 0.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)1
broad (>20)0
unknown0

Top tissues across cohort

TissueCohort genes
ileal mucosa1
male germ line stem cell (sensu Vertebrata) in testis1
pancreatic ductal cell1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
GCM29tissue_specificyesmale germ line stem cell (sensu Vertebrata) in testis, pancreatic ductal cell, ileal mucosa

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
GCM2892

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
GCM2O7560358.78

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
gliogenesis12808.7×0.001GCM2
parathyroid gland development12407.4×0.001GCM2
intracellular phosphate ion homeostasis11532.0×0.001GCM2
intracellular calcium ion homeostasis1145.3×0.010GCM2
transcription by RNA polymerase II170.5×0.017GCM2
regulation of transcription by RNA polymerase II111.7×0.086GCM2

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
GCM200

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1GCM2

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
GCM20

Clinical trials & evidence

Clinical trials

Clinical trials: 0.